Potent inhibitor of PARP-1 and PARP-2 (potency ≤5 nM in vitro).
AG-1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor.
A potent thiadiazolyl analog that binds to PH (pleckstrin homology) domain (Kd = 40.8 µM, Ki = 2.4 µM)..
A cell-permeable compound that directly and reversibly interacts with miRNA binding domain of Argonaute-2 (Kd = 126 µM) and inhibits binding of miR-20a, miR-26a, miR-107, miR-223 & let-7a to Ago2.
AS 1842856 is a potent and selective Foxo1 inhibitor (IC50 values are 33 nM at Foxo1 and >1 μM at Foxo3a and Foxo4)
Atglistatin is a potent, selective, and competitive inhibitor of ATGL (IC50 = 0.7 μM). It does not inhibit hormone-sensitive lipase, monoglyceride lipase, pancreatic lipase, lipoprotein lipase, or other lysophospholipases.
Bestatin is a protease Inhibitor that reversibly inhibits amino peptidases.
BLT-1 is a novel inhibitor of scavenger receptor BI (SR-BI).
A01 is a high affinity Smurf1 E3 ubiquitin ligase inhibitor (Kd = 3.7 nM). Attenuates Smurf1-mediated Smad 1/5 degradation and enhances BMP signaling. Potentiates BMP-2-induced osteoblastic activity in C2C12 myoblasts and MC3T3-E1 osteoblast precursor cells.
Bortezomib is a cell-permeable dipeptidylboronate compound that acts as a potent and selective 26S proteasome inhibitor. Human pancreatic cancer cell studies demonstrate Bortezomib to inhibit the PKR-like endoplasmic reticulum (ER) kinase and enhance ER stress, leading to apoptosis.
Bosutinib (SKI-606) is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to Imatinib or develop resistance during treatment.
CD532 is an inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the protein-protein interaction between N-Myc and Aurora A kinase.1 It also inhibits several cyclin-dependent kinases (CDKs), FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM.2 CD532 induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM.
